Pleconaril, a novel antipicornaviral agent.
Despite the availability of therapy for selected symptoms, no specific antiviral agents are available to treat or prevent infections due to the viruses of the Picornaviridae family--rhinoviruses and enteroviruses. Characterization of the three-dimensional structure of picornaviruses in the 1980s allowed development of compounds targeted at the virus itself. Pleconaril is a novel, orally available, systemically acting molecule whose pharmacokinetics are characterized by a two-compartment open model with first-order absorption and with a safety profile similar to that of placebo. It shows promising results in treatment of picornaviral respiratory tract infections, meningitis, and other life-threatening infections.
Florea
Naomi R
NR
Department of Pharmacy Research, Hartford Hospital, Hartford, Connecticut 06102, USA.
Maglio
Dana
D
Nicolau
David P
DP
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D019540:Area Under Curve; D001682:Biological Availability; D006207:Half-Life; D006801:Humans; D008875:Middle Aged; D010069:Oxadiazoles / Q000493:pharmacokinetics / Q000627:therapeutic use; D010080:Oxazoles; D010850:Picornaviridae Infections / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
D000998:Antiviral Agents; D010069:Oxadiazoles; D010080:Oxazoles; C115201:pleconaril